Alnylam Pharmaceuticals Inc’s filing revealed that its CMO & EVP Dev & Med Affairs Garg Pushkal unloaded Company’s shares for reported $1.63 million on Mar 24 ’25. In the deal valued at $300.00 per share,5,445 shares were sold. As a result of this transaction, Garg Pushkal now holds 20,221 shares worth roughly $5.46 million.
Then, Garg Pushkal sold 4,321 shares, generating $1,231,485 in total proceeds. Upon selling the shares at $285.00, the CMO & EVP Dev & Med Affairs now owns 20,221 shares.
Before that, PYOTT DAVID E I sold 7,440 shares. Alnylam Pharmaceuticals Inc shares valued at $2,224,560 were divested by the Director at a price of $299.00 per share. As a result of the transaction, PYOTT DAVID E I now holds 136 shares, worth roughly $36722.72.
Redburn Atlantic initiated its Alnylam Pharmaceuticals Inc [ALNY] rating to a Buy in a research note published on March 31, 2025; the price target was $353. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in late March from “a Neutral” to “an Overweight”. Wolfe Research also remained covering ALNY and has decreased its forecast on November 12, 2024 with a “an Underperform” recommendation from previously “Peer perform” rating. Scotiabank started covering the stock on October 16, 2024. It rated ALNY as “a Sector outperform”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock jump 0.58% to $270.02. Over the last five days, the stock has lost -7.11%. Alnylam Pharmaceuticals Inc shares have risen nearly 14.75% since the year began. Nevertheless, the stocks have risen 74.89% over the past one year. While a 52-week high of $304.39 was reached on 03/24/25, a 52-week low of $141.98 was recorded on 03/11/25. SMA at 50 days reached $260.11, while 200 days put it at $256.13.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 261.40, which if violated will result in even more drops to 252.77. On the upside, there is a resistance level at 275.25. A further resistance level may holdings at 280.47. The Relative Strength Index (RSI) on the 14-day chart is 56.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 8.12, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 49.90%. Stochastics %K at 53.74% indicates the stock is a holding.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2025-03-14, dropping by -0.68 million shares to a total of 2.54 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 3.22 million shares. There was a decline of -26.82%, which implies that there is a negative sentiment for the stock.
